[18F]FDG-PET in patients with Alzheimer's disease: Marker of disease spread

Dementia and Geriatric Cognitive Disorders

Volumn 19, Issue 1, 2005, Pages 24-30

  Bittner, D ^a   Gron G ^a   Schirrmeister, H ^a   Reske, S N ^a   Riepe, M W ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Alzheimer's disease; Dementia; FDG PET; Neuropsychology; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; LEARNING TEST; MINI MENTAL STATE EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECALL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; AMNESIA; BRAIN; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; IMAGE PROCESSING; MALE; MENTAL HEALTH; METABOLISM; MIDDLE AGED; PARIETAL LOBE; PHYSIOLOGY; SCINTISCANNING; SHORT TERM MEMORY; STATISTICS; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; AMNESIA; BLOOD GLUCOSE; BRAIN; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HIPPOCAMPUS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMORY, SHORT-TERM; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; STATISTICS; TEMPORAL LOBE;

EID: 10844257299     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080967     Document Type: Article

References (58)

1. Erkinjuntti T, Ostbye T, Steenhuis R, Hachinski V: The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667-1674.
2. Small GW, Rabins PV, Barry PP, Buckholtz NS, DeKosky ST, Ferris SH, Finkel SI, Gwyther LP, Khachaturian ZS, Lebowitz BD, McRae TD, Morris JC, Oakley F, Schneider LS, Streim JE, Sunderland T, Teri LA, Tune LE: Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-1371.
3. Criteria for the clinical diagnosis of Alzheimer's disease. Excerpts from the NINCDS-ADRDA Work Group report. J Am Geriatr Soc 1985;33:2-3.
4. Kosunen O, Soininen H, Paljarvi L, Heinonen O, Talasniemi S, Riekkinen PJS: Diagnostic accuracy of Alzheimer's disease: A neuropathological study. Acta Neuropathol (Berl) 1996;91:185-193.
5. Corey-Bloom J, Galasko D, Hofstetter CR, Jackson JE, Thal LJ: Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia. J Am Geriatr Soc 1993;41:31-37.
6. Fox NC, Freeborough PA, Rossor MN: Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 1996;348:94-97.
7. Jack CRJ, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E: Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484-489.
8. Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ, Soininen H: Hippocampus in Alzheimer's disease: A 3-year follow-up MRI study. Biol Psychiatry 2000;47:557-561.
9. Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW: Subjective memory complaints: Objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 2002;51:491-498.
10. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC: Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-1153.
11. Cutler NR, Haxby JV, Duara R, Grady CL, Kay AD, Kessler RM, Sundaram M, Rapoport SI: Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease. Ann Neurol 1985;18:298-309.
12. Alavi A, Dann R, Chawluk J, Alavi J, Kushner M, Reivich M: Positron emission tomography imaging of regional cerebral glucose metabolism. Semin Nucl Med 1986;16:2-34.
13. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL: Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol 1987;44:165-168.
14. Perani D, Di P, V, Vallar G, Cappa S, Messa C, Bottini G, Berti A, Passafiume D, Scarlato G, Gerundini P: Technetium-99m HM-PAO-SPECT study of regional cerebral perfusion in early Alzheimer's disease. J Nucl Med 1988;29:1507-1514.
15. Johnson KA, Holman BL, Mueller SP, Rosen TJ, English R, Nagel JS, Growdon JH: Single photon emission computed tomography in Alzheimer's disease. Abnormal iofetamine I 123 uptake reflects dementia severity. Arch Neurol 1988;45:392-396.
16. Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, Golomb J, Ferris SH, Reisberg B, Ciaravino J: Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 1992;49:1142-1150.
17. Eberling JL, Reed BR, Baker MG, Jagust WJ: Cognitive correlates of regional cerebral blood flow in Alzheimer's disease. Arch Neurol 1993;50:761-766.
18. Frey KA, Minoshima S, Kuhl DE: Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Q J Nucl Med 1998;42:166-178.
19. Hoffman JM, Welsh-Bohmer KA, Hanson M, Crain B, Hulette C, Earl N, Coleman RE: FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-1928.
20. Greene JD, Miles K, Hodges JR: Neuropsychology of memory and SPECT in the diagnosis and staging of dementia of Alzheimer type. J Neurol 1996;243:175-190.
21. Goldenberg G, Podreka I, Suess E, Deecke L: The cerebral localization of neuropsychological impairment in Alzheimer's disease: A SPECT study. J Neurol 1989;236:131-138.
22. van Gool WA, Walstra GJ, Teunisse S, Van der Zant FM, Weinstein HC, Van Royen EA: Diagnosing Alzheimer's disease in elderly, mildly demented patients: The impact of routine single photon emission computed tomography. J Neurol 1995;242:401-405.
23. Grady CL, Haxby JV, Horwitz B, Sundaram M, Berg G, Schapiro M, Friedland RP, Rapoport SI: Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1988;10:576-596.
24. Almkvist O: Neuropsychological features of early Alzheimer's disease: Preclinical and clinical stages. Acta Neurol Scand Suppl 1996;165:63-71.
25. Vargha-Khadem F, Gadian DG, Watkins KE, Connelly A, Van Paesschen W, Mishkin M: Differential effects of early hippocampal pathology on episodic and semantic memory. Science 1997;277:376-380.
26. Zola-Morgan S, Squire LR: Neuroanatomy of memory. Annu Rev Neurosci 1993;16:547-563.
27. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL: Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170.
28. Ball MJ, Fisman M, Hachinski V, Blume W, Fox A, Kral VA, Kirshen AJ, Fox H, Merskey H: A new definition of Alzheimer's disease: A hippocampal dementia. Lancet 1985;I:14-16.
29. Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR: Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann Neurol 1986;20:472-481.
30. Hyman BT: The neuropathological diagnosis of Alzheimer's disease: Clinical-pathological studies. Neurobiol Aging 1997;18:S27-S32.
31. Ishii K, Sasaki M, Yamaji S, Sakamoto S, Kitagaki H, Mori E: Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Disord 1998;9:317-322.
32. Yamaguchi S, Meguro K, Itoh M, Hayasaka C, Shimada M, Yamazaki H, Yamadori A: Decreased cortical glucose metabolism correlates with hippocampal atrophy in Alzheimer's disease as shown by MRI and PET. J Neurol Neurosurg Psychiatry 1997;62:596-600.
33. Schmidt KH, Metzler P: WST - Wortschatztest. Beltz, Weinheim, 1992.
34. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
35. Kaplan EF, Goodglass H, Weintraub S: The Boston Naming Test. Philadelphia, Lea & Febiger, 1993.
36. Wechsler D: Wechsler Memory Scale - Revised Manual. San Antonio, The Psychological Corporation, 1987.
37. Nelson HE: A modified card-sorting test sensitive to frontal lobe defects. Cortex 1976;12:313-324.
38. Reitan RM: Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-276.
39. Delis DC, Kramer JH, Kaplan E, Ober BA: California Verbal Learning Test. New York, Psychological Corporation, 1987.
40. Shulman KI: Clock-drawing: Is it the ideal cognitive screening test? Int J Geriatr Psychiatry 2000;15:548-561.
41. Zimmermann P, Frimm A: Testbatterie zur Aufmerksamkeitsprüfung. TAP (V. 1.02). Psytest, Würselen, 1994.
42. Schmidlin P: Improved iterative image reconstruction using variable projection binning and abbreviated convolution. Eur J Nucl Med 1994;21:930-936.
43. Ashburner J, Friston KJ: Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999;7:254-266.
44. Talairach J, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. Stuttgart, Thieme, 1988.
45. Herholz K, Adams R, Kessler J: Criteria for the diagnosis of Alzheimer's disease with positron emission tomography. Dementia 1990;1:156-164.
46. Soininen H, Helkala EL, Kuikka J, Hartikainen P, Lehtovirta M, Riekkinen PJ, Sr: Regional cerebral blood flow measured by 99mTc-HMPAO SPECT differs in subgroups of Alzheimer's disease. J Neural Transm Park Dis Dement Sect 1995;9:95-109.
47. Ishii K, Kitagaki H, Kono M, Mori E: Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET. J Nucl Med 1996;37:1159-1165.
48. Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ: Choice of reference region in the quantification of single-photon emission tomography in primary degenerative dementia. Eur J Nucl Med 1994;21:503-508.
49. Herholz K: FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 1995;9:6-16.
50. Cutler NR, Haxby JV, Duara R, Grady CL, Moore AM, Parisi JE, White J, Heston L, Margolin RM, Rapoport SI: Brain metabolism as measured with positron emission tomography: Serial assessment in a patient with familial Alzheimer's disease. Neurology 1985;35:1556-1561.
51. Desgranges B, Baron JC, de LS, V, Petit-Taboue MC, Benali K, Landeau B, Lechevalier B, Eustache F: The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization. Brain 1998;121:611-631.
52. Rapoport SI: Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: A critical review. Cerebrovasc Brain Metab Rev 1991;3:297-335.
53. 18F]FDG PET metabolic study. Brain 1993;116:903-919.
54. Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E: Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci 2002;200:27-32.
55. 18F-fluoro-2-deoxy-D-glucose in Alzheimer's disease and frontotemporal dementia at initial diagnosis. Eur Neurol 2001;45:19-27.
56. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
57. Nagy Z, Hindley NJ, Braak H, Braak E, Yilmazer-Hanke DM, Schultz C, Barnetson L, King EM, Jobst KA, Smith AD: The progression of Alzheimer's disease from limbic regions to the neocortex: Clinical, radiological and pathological relationships. Dement Geriatr Cogn Disord 1999;10:115-120.
58. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.